UK Cannabis Rescheduling 2018: How Medical Cannabis Became Legal

UK Cannabis Rescheduling 2018: How Medical Cannabis Became Legal

On 19 November 2018, the United Kingdom took a significant regulatory step when the government announced that cannabis would be rescheduled from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations 2001. This historic decision marked a turning point in British medicine, allowing medical cannabis to be prescribed by specialist physicians for the first time in decades. Understanding what happened in 2018 and how the regulatory landscape has evolved since remains crucial for patients, healthcare professionals, and advocates seeking to navigate the UK’s approach to medicinal cannabis.

The Background: Why Cannabis Was Rescheduled

Prior to November 2018, cannabis was classified as a Schedule 1 drug in the UK, a classification reserved for substances with no recognised medical value. This meant that cannabis could not be prescribed, possessed, or used for any medical purpose, regardless of clinical evidence. The regulatory change followed growing international evidence and persistent calls from medical professionals, patient advocacy groups, and scientists demonstrating therapeutic potential for certain cannabinoid-based medicines in treating conditions such as epilepsy, chronic pain, and chemotherapy-induced nausea.

The Home Office’s decision to reschedule came partly in response to high-profile cases, including that of Billy Caldwell, a young epilepsy patient whose parents campaigned for access to cannabis oil after conventional treatments failed. These cases, combined with emerging clinical research and recommendations from the Advisory Council on the Misuse of Drugs (ACMD), prompted the government to reassess cannabis’s Schedule 1 status.

What Rescheduling Meant: From Schedule 1 to Schedule 2

Moving cannabis to Schedule 2 represented a fundamental shift in its legal status. Schedule 2 classification indicates that a substance has accepted medical uses and can be prescribed by specialist doctors. This change enabled registered medical practitioners working in specialist settings—such as hospital consultants—to prescribe cannabis-based medicinal products to patients for whom conventional treatments had proven ineffective.

However, it is important to note that Schedule 2 status does not mean cannabis became available on the NHS immediately or universally. The Medicines and Healthcare products Regulatory Agency (MHRA), the UK’s medicines regulator, maintains separate approval processes for cannabis-based products. Only those products that meet the MHRA’s standards for safety, quality, and efficacy can be legally prescribed. Currently, only a limited number of cannabis-based medicines have received MHRA authorisation, including Sativex (a cannabis-derived oromucosal spray for multiple sclerosis) and Epidyolex (a purified cannabidiol product for certain rare epilepsy types).

The Current Landscape: Accessing Medical Cannabis in the UK

Since 2018, patients seeking access to medical cannabis UK have faced a complex pathway. While rescheduling created the legal framework, access remains restricted and requires specialist evaluation. The NHS initially adopted a cautious approach, with most Integrated Care Boards (ICBs) limiting or refusing funding for cannabis-based medicines. This meant that many patients who could legally be prescribed cannabis faced financial barriers, as treatment could cost between £300 and £1,000 per month depending on the product and dosage.

To address these barriers, private specialist clinics emerged offering consultations and prescriptions for unlicensed cannabis-based products. Organisations like the British Private best UK cannabis clinicss Association have attempted to establish standards within the private sector, though regulation remains inconsistent. Meanwhile, Project Twenty21, a research initiative, provided eligible patients with access to cannabis treatments whilst contributing to the evidence base surrounding medicinal cannabis outcomes.

In 2024, there remains limited NHS availability of cannabis-based medicines. Most prescriptions are issued in the private sector, and access depends on meeting specific clinical criteria, undergoing specialist assessment, and demonstrating that conventional treatments have failed.

NHS Guidance and NICE’s Position

The National Institute for Health and Care Excellence (NICE) has not issued comprehensive guidance recommending routine NHS funding for most cannabis-based medicines for the conditions historically discussed in the media. NICE’s approach reflects the current evidence base, which—whilst growing—is described by the organisation as limited in certain areas. This means that unlike some other medications, cannabis-based treatments are not typically available through standard NHS pathways for most conditions.

According to reports, estimated numbers of NHS prescriptions for cannabis-based medicines across England remain in the low hundreds annually, representing a small fraction of the patient population that might theoretically benefit. This disconnect between legal rescheduling and practical NHS availability has been a source of frustration for patient groups and healthcare advocates.

Understanding Your Rights Under Current UK cannabis law

It is crucial for patients to understand that rescheduling cannabis does not mean it is freely available or decriminalised for personal use. Cannabis remains illegal for recreational purposes, and possession without a valid prescription remains a criminal offence. However, patients who obtain cannabis through a legal prescription from a specialist doctor are protected from prosecution under the Misuse of Drugs Act 1971.

For patients considering medical cannabis treatment, the pathway typically involves: consulting with a GP who may refer to a specialist clinic, undergoing assessment by a doctor registered to prescribe cannabis-based medicines, establishing that conventional treatments have failed or are unsuitable, and, if approved, receiving a private prescription. Patients must then obtain their medication from a licensed pharmacy authorised to dispense cannabis-based medicines.

The Evidence and Future Prospects

Since rescheduling, the evidence base for cannabis-based medicines has continued to grow, particularly in conditions such as treatment-resistant epilepsy, multiple sclerosis spasticity, and chemotherapy-related nausea. However, according to reports, many clinical trials remain ongoing, and additional robust evidence is needed to support wider NHS adoption.

The Medical Cannabis Registry, established to track patient outcomes and adverse effects, has been instrumental in collecting real-world evidence. As this data accumulates and further clinical research is published, it is anticipated that NICE’s recommendations and NHS funding decisions may evolve, potentially improving access for eligible patients.

The 2018 rescheduling represented genuine progress in recognising cannabis’s medical potential. However, the gap between legal availability and practical access reflects ongoing challenges in translating regulatory change into equitable patient care. For patients seeking medical cannabis treatment, understanding both their legal rights and the realistic pathways to accessing treatment remains essential.

Frequently Asked Questions

Can I legally grow cannabis at home if I have a medical need?

No. Despite rescheduling, home cultivation of cannabis remains illegal in the UK, even for medical purposes. Patients must obtain cannabis-based medicines through legal prescriptions dispensed by licensed pharmacies. Growing cannabis without authorisation constitutes a criminal offence under the Misuse of Drugs Act 1971, regardless of medical intent.

Will my NHS GP prescribe medical cannabis?

Most GPs cannot prescribe cannabis-based medicines, as prescribing is restricted to specialist doctors working in appropriate settings. GPs can, however, refer patients to specialist clinics for evaluation. Referral does not guarantee prescription, as specialists must assess whether conventional treatments have failed and whether the patient meets specific clinical criteria.

What conditions can be treated with medical cannabis in the UK?

Whilst cannabis has been rescheduled, NICE has not recommended routine NHS use for most conditions. Specialists may consider cannabis for conditions including epilepsy (particularly treatment-resistant epilepsy), multiple sclerosis spasticity, and certain chronic pain conditions where conventional treatments have failed. However, approval depends on individual patient assessment and specialist clinical judgment.

“`

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Medical cannabis is a prescription-only medicine in the UK. Always consult a qualified healthcare professional. CannaZen is an information platform, not a medical provider.